Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

2016 • 29,943 citations

Regression Models and Life-Tables

1992 • 27,454 citations

Regression Models and Life-Tables

1972 • 27,145 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 • 14,809 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2012 • 11,574 citations

World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects

2003 • 10,838 citations

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

2015 • 5,267 citations

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

2002 • 4,625 citations

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1934 • 4,169 citations

Nivolumab plus Ipilimumab in Advanced Melanoma

2013 • 4,054 citations

Cancer immunotherapy comes of age

2011 • 3,453 citations

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 • 3,044 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

2010 • 2,721 citations

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2014 • 2,088 citations

Tests for Linear Trends in Proportions and Frequencies

1955 • 2,021 citations

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

2012 • 1,988 citations

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8⁺T lymphocytes are prognostic factors of human ovarian cancer

2007 • 1,317 citations

Cancer despite immunosurveillance: immunoselection and immunosubversion

2006 • 1,263 citations

Phase 3 trial of everolimus for metastatic renal cell carcinoma

2010 • 1,125 citations

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

2016 • 1,081 citations

Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma

2004 • 778 citations

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

2013 • 697 citations

Mechanisms of Immune Evasion by Tumors

2006 • 665 citations

Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing Mice

1992 • 650 citations

Cancer Immunotherapy Comes of Age

2011 • 560 citations

Kidney Cancer

2009 • 463 citations

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

2017 • 452 citations

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

2013 • 386 citations

Codes and Declarations

2002 • 355 citations

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2012 • 271 citations

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

2014 • 255 citations

Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

2014 • 137 citations

High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor

2007 • 119 citations

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

2013 • 117 citations

Tumor Biology and Prognostic Factors in Renal Cell Carcinoma

2011 • 107 citations

Molecular mechanisms of T‐cell tolerance

2011 • 81 citations

Evidence for drugs and biomarkers in oncology guidelines (GLs): A survey of the National Comprehensive Cancer Network (NCCN) colon cancer panel.

2011 • 58 citations

Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.

2014 • 55 citations

Novel Immunotherapeutic Strategies in Development for Renal Cell Carcinoma

2012 • 45 citations

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy

2013 • 31 citations

Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis.

2013 • 10 citations